KYLEENA®
A 5-YEAR 
LOW DOSE IUS

Kyleena® (levonorgestrel [LNG]-releasing intrauterine system (IUS) [19.5 mg]) is indicated for conception control for up to 5 years.

Click here for additional safety information and for a link to the product monograph discussing:

  • Contraindications: known or suspected pregnancy; current or recurrent pelvic inflammatory disease or conditions associated with increased risk for pelvic infections; postpartum endometritis or septic abortion during the previous three months; abnormal uterine bleeding of unknown etiology; congenital or acquired uterine anomaly including fibroids, that distort the uterine cavity; uterine or cervical malignancy; known or suspected progestogen-dependent neoplasia, including breast cancer; cervicitis or vaginitis, including bacterial vaginosis or other lower genital tract infections until infection is controlled; cervical dysplasia; active liver disease or dysfunction; actual benign or malignant liver tumours; hypersensitivity to levonorgestrel or any of the other ingredients in the formulation or component of the container components of Kyleena®; a previously inserted intrauterine contraceptive (IUC) that has not been removed; recent trophoblastic disease while hCG levels are elevated; bacterial endocarditis
  • Most serious warnings and precautions regarding sexually transmitted infections (STIs), cigarette smoking and uterine perforation
  • Other relevant warnings and precautions regarding: post-menarcheal adolescents under the age of 18; breast-feeding; contraceptive use; breast cancer; cardiovascular disease; hypertension; heart disease; diabetic patients; bleeding patterns; arterial and venous thromboembolism; VTE; liver function; jaundice; headache or migraine; eye problems; depression; ectopic pregnancy; expulsion of Kyleena®; ovarian cysts/enlarged ovarian follicles; PID; sepsis; informing patient of efficacy risks and side effects of Kyleena®; thorough history and physical examination prior and following insertion

KYLEENA®
A 5-YEAR 
LOW DOSE IUS

Kyleena® (levonorgestrel [LNG]-releasing intrauterine system (IUS) [19.5 mg]) is indicated for conception control for up to 5 years.

Click here for additional safety information and for a link to the product monograph discussing:

  • Contraindications: known or suspected pregnancy; current or recurrent pelvic inflammatory disease or conditions associated with increased risk for pelvic infections; postpartum endometritis or septic abortion during the previous three months; abnormal uterine bleeding of unknown etiology; congenital or acquired uterine anomaly including fibroids, that distort the uterine cavity; uterine or cervical malignancy; known or suspected progestogen-dependent neoplasia, including breast cancer; cervicitis or vaginitis, including bacterial vaginosis or other lower genital tract infections until infection is controlled; cervical dysplasia; active liver disease or dysfunction; actual benign or malignant liver tumours; hypersensitivity to levonorgestrel or any of the other ingredients in the formulation or component of the container components of Kyleena®; a previously inserted intrauterine contraceptive (IUC) that has not been removed; recent trophoblastic disease while hCG levels are elevated; bacterial endocarditis
  • Most serious warnings and precautions regarding sexually transmitted infections (STIs), cigarette smoking and uterine perforation
  • Other relevant warnings and precautions regarding: post-menarcheal adolescents under the age of 18; breast-feeding; contraceptive use; breast cancer; cardiovascular disease; hypertension; heart disease; diabetic patients; bleeding patterns; arterial and venous thromboembolism; VTE; liver function; jaundice; headache or migraine; eye problems; depression; ectopic pregnancy; expulsion of Kyleena®; ovarian cysts/enlarged ovarian follicles; PID; sepsis; informing patient of efficacy risks and side effects of Kyleena®; thorough history and physical examination prior and following insertion
Alt tag